Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Each injectable IV product will have the osmolarity listed on the label located on the vial
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
We used 3 nmol kg 1 of tirzepatide, identified as a maximal dose for glucose lowering in wild-type mice (Extended Data Fig
Both Ozempic (Semaglutide) and Mounjaro (Tirzepatide) are GLP-1 receptor agonists (Mounjaro adds GIP)
Product Authenticity and Quality Assurance Every unit of NAD+ B12 Synedica is verified for authenticity
Designed to retain the fat-reducing effects of HGH without influencing growth or insulin-like growth factor 1 levels, AOD9604 has gained attention for its potential as an anti-obesity and metabolic treatment
